<DOC>
	<DOCNO>NCT02559713</DOCNO>
	<brief_summary>The purpose study assess concentration vedolizumab breast milk lactate woman active ulcerative colitis ( UC ) Crohn 's disease ( CD ) receive vedolizumab therapeutically .</brief_summary>
	<brief_title>Postmarketing Vedolizumab Milk-Only Lactation Study Lactating Women With Active Ulcerative Colitis Crohn 's Disease</brief_title>
	<detailed_description>The drug test study call vedolizumab . This post-marketing milk-only lactation study assess concentration vedolizumab breast milk lactate woman active UC CD receive vedolizumab therapeutically . The study enroll approximately 12 participant . All participant receive establish vedolizumab maintenance regimen ( least two 300 mg dos vedolizumab every 8 week prior delivery infant one 300 mg dose vedolizumab postpartum ) receive schedule dose vedolizumab day 1 study clinic , study site healthcare provider ( HCP ) office : 30-minute IV infusion 300 mg vedolizumab . This multi-center trial conduct United States . The overall time participate study 3 month . Participants make visit clinic , study site HCP office Screening , Check-in ( Day -1 ) . Visits Days 4 , 8 , 15 , 29. may complete participant 's home setting presence qualify nurse , clinic , study site HCP office . The study exit/follow-up safety assessment occur Day 57 ( ±3 ) .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<criteria>nclusion Criteria : 1 . Is capable understand comply protocol requirement . 2 . Signs date write , informed consent form require privacy authorization prior initiation study procedure . 3 . Is female least 18 year age time informed consent . 4 . A female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent throughout duration study . 5 . Is establish vedolizumab maintenance therapy ( receive least two 300 mg vedolizumab IV every 8 week dose prior delivery infant one 300 mg every 8 week dose vedolizumab postpartum ) , commence participant 's treat physician treatment active UC CD prior enrol study . 6 . Has deliver single , normal term infant ( least 37 week ' gestation ) , motherinfant pair require . 7 . Is least 6 week postpartum Day 1 . 8 . Lactation well establish mother exclusively breast feed infant ( provide 1 supplemental bottle formula/day ) enrol study . 9 . Participant independently decide treated vedolizumab breastfeed prior provide consent participate study . 10 . Plans continue breastfeed least throughout duration study . 11 . Agrees use emollient nipple cream recommend investigator use sampling period . 1 . Has receive investigational compound approve biologic biosimilar agent , except vedolizumab within 60 day prior enrollment study . Within 30 day prior enrollment , participant receive follow treatment underlying disease : Nonbiologic therapy [ example ( eg ) , cyclosporine ] , list protocol . An approved nonbiologic therapy investigational protocol . 3 . Is expect receive additional vedolizumab treatment Day 2 Study Exit/Followup ( Day 57 ) . 4 . Has receive natalizumab treatment . 5 . Has receive live vaccination within 30 day prior vedolizumab administration . 6 . Has positive test result hepatitis B surface antigen , antibody hepatitis C virus , Screening know history human immunodeficiency virus infection ( eg , common variable immunodeficiency , human immunodeficiency virus infection , organ transplantation ) . 7 . Has clinically significant infection ( eg , pneumonia , pyelonephritis ) chronic infection within 30 day prior enrollment . 8 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 9 . Has evidence unstable uncontrolled , clinically significant cardiovascular , central nervous system , pulmonary , hepatic , renal , gastrointestinal , genitourinary , hematological , coagulation , immunological , endocrine/metabolic medical disorder , include serious allergy , asthma , hypoxemia , hypertension , seizures allergic skin rash , opinion investigator , would confound study result compromise participant safety . Additionally , find participant 's medical history , physical examination , safety laboratory test give reasonable suspicion disease would contraindicate take vedolizumab , similar drug might interfere conduct study . 10 . Had surgical procedure require general anesthesia within 30 day prior enrollment plan undergo major surgery study period . 11 . Has history malignancy , except follow : ( ) adequately treat nonmetastatic basal cell skin cancer ; ( b ) squamous cell skin cancer adequately treat recur least 1 year prior enrollment ; ( c ) history cervical carcinoma situ adequately treat recur least 3 year prior enrollment . Participants remote history malignancy ( eg , great ( &gt; ) 10 year since completion curative therapy without recurrence ) consider base nature malignancy therapy receive must discuss sponsor casebycase basis prior enrollment . 12 . Has history major neurological disorder , include stroke , multiple sclerosis , brain tumor , neurodegenerative disease . 13 . Has positive progressive multifocal leukoencephalopathy subjective symptom checklist screening . Has follow laboratory abnormality Screening Period : Hemoglobin level &lt; 8 g/dL . White blood cell ( WBC ) count &lt; 3*10^9/L . Lymphocyte count &lt; 0.5*10^9/L . Platelet count &lt; 100×109/L &gt; 1200*10^9/L . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 3*the upper limit normal ( ULN ) . Alkaline phosphatase &gt; 3*ULN . Serum creatinine &gt; 2*ULN . 15 . Has current recent history ( within 1 year prior enrollment ) alcohol dependence illicit drug use . 16 . Has active psychiatric problem , investigator 's opinion , may interfere compliance study procedure . 17 . Is unable participate study visit comply study procedure . 18 . Has history breast implant , breast augmentation , breast reduction surgery . 19 . Has prior history difficulty establish lactation . 20 . Has positive urine/blood drug result drug abuse ( define illicit drug use ) Screening . 21 . Has take exclude medication , supplement , food product time period list Excluded Medications Dietary Products table . 22 . Has donate lose 450 milliliter blood volume ( include plasmapheresis ) , transfusion blood product within 45 day prior Day 1 . 23 . Has abnormal ( clinically significant ) electrocardiogram ( ECG ) Screening . Entry participant abnormal ( clinically significant ) ECG must approve , document signature principal investigator ( PI ) delegate . 24 . Has abnormal screen laboratory value suggest clinically significant underlying disease .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Lactation</keyword>
	<keyword>Lactating Women</keyword>
	<keyword>Vedolizumab</keyword>
	<keyword>Colitis Ulcerative</keyword>
	<keyword>Crohn Disease</keyword>
	<keyword>Crohn 's</keyword>
</DOC>